9.80
+14.09%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Senseonics Holdings
From its filings with the US Securities and Exchange Commission
Senseonics Holdings is based in Germantown, Maryland and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker SENS. The SEC classifies its business as industrial instruments for measurement, display, and control. In the fiscal year to 31 December 2025, it reported revenue of $35.3m and a net loss of $69.1m. At that date it held total assets of $126.3m and shareholders' equity of $61.0m.
We are a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (“CGM”) system to improve the lives of people with diabetes by enhancing their ability to manage their disease with relative ease and accuracy. Our implantable CGM system (“Eversense”), including Eversense E3 and Eversense 365 CGM systems are designed to continually and accurately measure glucose levels in people with diabetes via an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management for a period of up to twelve months in the case of Eversense 365 and six months in the case of Eversense E3, as compared to seven to 15 days for non-implantable CGM systems. In September 2024, the 365-day extended life Eversense E3 CGM system was approved by the FDA and, through Ascensia Diabetes Care Holdings AG (“Ascensia”), we began commercializing Eversense 365 in the fourth quarter of 2024. In January 2026, we took over full commercial responsibility for Eversense 365 in the United States and began marketing and distributing the product with our own sales force. In June 2022, we affixed the CE Mark to the Eversense E3 CGM system and Ascensia began commercialization in select markets in Europe during the third quarter of 2022. In January 2026, the Company obtained CE Mark approval for Eversense 365 and expects to launch Eversense 365 in the European Territories by the second half of 2026.
Quoted from its 10-K, filed 2 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 4 Mar 2015
- Employees
- 130
- Website
- senseonics.com ↗
- Head office
- 20451 SENECA MEADOWS PARKWAY, GERMANTOWN, MD, 20876
- Incorporated in
- DE
- Classification
- Industrial Instruments For Measurement, Display, and Control
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. Stephen DefalcoIndependent Chairman of the Board$207,500
- Dr. Timothy GoodnowPresident, Chief Executive Officer, Director, since 2015$3.3m
- Mr. Frederick SullivanChief Financial Officer, Treasurer, Secretary
- Dr. Mukul JainChief Operating Officer$1.9m
- Mr. Kenneth HortonGeneral Counsel, Corporate Development Advisor$1.3m
- Dr. Francine KaufmanChief Medical Officer, Director, since 2019$1.2m
- Mr. Brian HansenDirector, Chief Commercial Officer
- Dr. Steven EdelmanIndependent Director$164,000
- Mr. Edward FiorentinoIndependent Director$169,000
- Ms. Sharon LarkinIndependent Director$159,000
- Mr. Douglas PrinceIndependent Director$177,500
- Mr. Douglas RoederIndependent Director$171,500
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 34
- Environment
- 37
- Social
- 31
- Governance
- 32
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Senseonics offers Eversense, an implantable CGM system for diabetes management with real-time glucose monitoring.
- Eversense features a sensor, smart transmitter, and mobile app for continuous glucose tracking and alerts.
- Senseonics has 191 full-time employees focused on glucose monitoring system development and commercialization.
Weaknesses
- Senseonics' Eversense system requires subcutaneous sensor insertion by healthcare providers for glucose monitoring.
- The company's business is limited to the glucose monitoring systems segment with no other product lines.
- Senseonics' IPO occurred in 2015, indicating a relatively recent market entry.
Opportunities
- Senseonics can expand Eversense usage in the US diabetes management market with growing demand.
- The company may target international markets for Eversense adoption beyond the US.
- Eversense's mobile app compatibility with Apple Watch and smartphones offers integration opportunities.
Threats
- Senseonics faces competition from other glucose monitoring systems in the Health Care sector.
- The company's reliance on a single product line, Eversense, poses market risk.
- Regulatory changes in the Health Care industry could impact Eversense's commercialization.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.